# Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment

> **NCT00538291** · PHASE2 · TERMINATED · sponsor: **City of Hope Medical Center** · enrollment: 13 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** capecitabine
- **GENETIC:** gene expression analysis
- **GENETIC:** microarray analysis
- **GENETIC:** polymorphism analysis
- **GENETIC:** reverse transcriptase-polymerase chain reaction
- **OTHER:** immunohistochemistry staining method

## Key facts

- **NCT ID:** NCT00538291
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2009-02
- **Final completion:** —
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Study was terminated early due to lack of efficacy.
- **Last updated:** 2014-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00538291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00538291, "Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00538291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*